Triheptanoin: Phase II started

Ultragenyx began a double-blind, placebo-controlled, international Phase II trial to evaluate oral triheptanoin given 4 times daily in up to 50 patients ages 3-17

Read the full 244 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE